Nymox

Nymox

March 17, 2005 12:47 ET

Two New Studies Document Dangers of Second Hand Smoke and Fetal Exposure to Maternal Smoking


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX

NASDAQ SYMBOL: NYMX

MARCH 17, 2005 - 12:47 ET

Two New Studies Document Dangers of Second Hand Smoke
and Fetal Exposure to Maternal Smoking

MAYWOOD, N.J.--(CCNMatthews - Mar 17, 2005) -

Nymox (NASDAQ:NYMX) TobacAlert™ Product to Detect Second Hand Smoke
Exposure Now Available at CVS Pharmacies Nationwide

Two new studies have highlighted the relevance of Nymox's (NASDAQ:NYMX)
TobacAlert™ product for measuring smoking and second hand smoke
exposure. The first study is published in the current Journal of the
American Medical Association (JAMA March 9, 2005, 293:1212-1222) and
documents that cells from fetuses (obtained from amniotic fluid) whose
mothers smoked during pregnancy had higher levels of chromosomal
abnormalities, damage, and instability. This research was done in Spain
at the Universitat Autonoma Barcelona by a team of researchers led by
Dr. Rosa de la Chica. Mutations in the genetic material of the
developing fetus raises the possibility that smoking during pregnancy
may put children at risk of developing cancer later in life.

A second new study published in the British Medical Journal (BMJ online,
March 2, 2005) estimates that up to 10,000 or more deaths per year in
the United Kingdom could be attributed to second hand smoke exposure.
This study published research from the University of Queensland in
Australia and was written by Dr. Konrad Jamrozik. The study estimated
that up to 600 cases per year in the UK die from workplace exposure to
second hand smoke.

TobacAlert™ is Nymox's revolutionary new product that allows
concerned individuals to determine second hand smoke exposure by
measuring the level of cotinine, a metabolite of nicotine, in urine.
TobacAlert™ is a quick, accurate and easy to use test that can be
done almost anywhere, including at home, the workplace or school and
that requires no instruments to use. More information about
TobacAlert™ is available at www.tobacalert.com.

"I do not believe people understand how much of an impact their smoking
can have on those around them. TobacAlert™ provides everyone with a
simple, easy-to-use way of measuring exposure," said Brian Doyle,
Nymox's Global Sales Manager.

TobacAlert™ is available at approximately 5,400 CVS/pharmacy®
stores across the U.S. as well as online at www.cvs.com.

TobacAlert™ uses patented technology to provide a semi-quantitative
measure of cotinine, a by-product of the body's metabolism of nicotine.
Cotinine is widely accepted and commonly used in medical research and
public health studies to determine the extent of tobacco product
exposure. TobacAlert™ is intended only to assess an individual's
level of tobacco product exposure and not for any medical treatment
purposes.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com